The Probiotic Strain Problem: Why a Species Name May Not Be Enough to Support Your Product Claims
A probiotic product can correctly identify a species and still have a serious evidence problem. Probiotic strain claims become vulnerable when the research used to support them does not adequately match the strain in the product. Different strains within the same species can produce different effects, so the real question is not simply whether research exists on the species. It is whether that research actually supports the strain, dose, product and claim you are using.
← Back to InsightsNot automatically. A shared species name does not establish the same clinical effect. If your product contains a different strain from the one used in the research, you need a scientific basis for concluding that the evidence applies to your product.
Consider Bifidobacterium bifidum. There are multiple strains within this species. Those strains may share important biological characteristics, but they are not automatically identical in how they behave or in the effects they produce.
This matters when a company finds a strong study on one B. bifidum strain and assumes that the study supports a product containing another strain simply because both have the same species name.
The species match is relevant, but it is not proof that the clinical effect transfers.
Where the Probiotic Strain Problem Begins
Probiotic identity does not stop at the species level.
Genus: Bifidobacterium
Species: bifidum
Strain: the specific strain designation that identifies the microorganism used in the product or study.
That final level can be scientifically important. Strains within the same species can differ in genomic features, metabolic activity, adhesion, interactions with intestinal cells, immune effects and other functional characteristics.
Laboratory studies comparing different Bifidobacterium strains have demonstrated different immune responses between strains. Research examining B. bifidum strains has also found differences in their effects on intestinal epithelial barrier function.
These laboratory findings do not prove that every biological difference will produce a different clinical outcome in humans. They establish a more important point: species identity alone cannot demonstrate that two strains are functionally or clinically equivalent.
Same Species Does Not Guarantee the Same Effect
Clinical research provides a useful illustration.
In one study, researchers directly compared probiotic products containing two strains reported in the study as Lactobacillus casei DN-114001 and Lactobacillus casei Shirota.
Antibiotic-associated diarrhea occurred in 6.7% of participants receiving the DN-114001 product compared with 33.3% of those receiving the Shirota product.
The probiotics shared the same reported species classification, but the observed clinical outcomes were not the same.
This does not mean every pair of strains within a species must produce different effects.
It means you cannot assume that two strains will produce the same clinical effect simply because their species name matches.
How a Probiotic Claim Develops an Evidence Gap
Imagine a company wants to market a probiotic with the claim:
“Supports digestive health and regularity.”
The formulation contains one particular strain of Bifidobacterium bifidum.
The company finds a well-designed randomized clinical trial showing a digestive benefit from another B. bifidum strain and adds the study to its substantiation file.
Same genus. Same species. Similar product category.
But that still leaves several questions unanswered.
| What needs checking | What you need to know |
|---|---|
| Strain | Was the strain in your product actually used in the study? If not, what evidence supports extrapolating the result? |
| Dose | Is the amount consumers receive reasonably consistent with the dose associated with the demonstrated effect? |
| Clinical outcome | Did the trial measure the benefit your marketing actually promises, or something different? |
| Population | Were the people studied relevant to the consumers for whom you are making the claim? |
| Formulation | Could the delivery system, product matrix or other formulation factors materially affect performance? |
| Viability | Does the product maintain the required viable count through the period in which consumers are expected to use it? |
| Total evidence | Do other studies support the proposed effect, or are there conflicting findings that change the conclusion? |
A study can be scientifically strong and still be poor substantiation for your product.
The problem may not be the quality of the study. The problem may be applicability.
Can Evidence From Another Strain Ever Be Used?
Potentially, but the scientific bridge needs to be justified.
A company should not begin with:
“They are the same species, so the evidence applies.”
The better question is:
“What evidence demonstrates that this result can reasonably be extrapolated to the strain in our product?”
That assessment may require consideration of strain identity, relevant genomic and phenotypic characteristics, mechanism of action, dose, formulation, population, clinical endpoint and the wider evidence base.
The level of support needed will depend partly on the claim and how far the actual product differs from what was studied.
The central point is simple: the species name itself is not the evidence bridge.
What About Research That Combines Different Probiotic Strains?
Pooled probiotic evidence needs careful interpretation because combining multiple organisms can hide meaningful differences between them.
A systematic review evaluating 228 controlled probiotic trials found evidence that efficacy can vary by both probiotic strain and clinical indication. The authors cautioned against assuming that results from one probiotic preparation automatically apply to another.
At the same time, the clinical literature is not complete enough to conclude that every probiotic effect is always unique to a single strain.
A later pediatric review examining randomized trials of different strains within the same species found relatively few direct head-to-head comparisons. The available evidence therefore did not establish universal strain-specificity across every condition studied.
These findings lead to a more useful conclusion for companies:
Different strains can produce different effects, and strain interchangeability should not be assumed. Whether evidence can be extrapolated has to be evaluated for the particular strain, biological effect and clinical claim.
Clinical and mechanistic data demonstrate meaningful strain-level heterogeneity. McFarland et al. evaluated 228 controlled probiotic trials and identified both strain-specific and disease-specific efficacy across prevention and treatment indications. In a direct clinical comparison, antibiotic-associated diarrhea occurred in 6.7% of participants receiving the DN-114001 preparation versus 33.3% receiving the Shirota preparation (p=0.021), despite both strains being reported under the same species classification. Mechanistic studies comparing Bifidobacterium isolates have likewise demonstrated strain-dependent cytokine responses and differences in epithelial barrier effects. These findings do not establish universal strain-specificity for every probiotic outcome, but they show why species-level taxonomic identity alone cannot establish biological or clinical equivalence.
Where Probiotic Strain Claims Usually Break Down
A probiotic strain claim can look well supported until the evidence is examined against the product itself.
The strain may be different from the one studied. The dose may not match. The clinical trial may have measured a different outcome, used a different population, or tested the probiotic in a formulation that is not comparable with the commercial product.
Even when each individual study appears credible, the overall evidence may contain conflicting findings or may not justify transferring an effect from one strain to another.
These are not always problems that can be identified simply by checking whether a study exists.
The difficult part is determining whether the evidence is actually applicable to the product and whether the scientific bridge from study to claim can be defended.
That assessment becomes particularly important when:
- the product uses evidence generated with another strain;
- several strains are combined in one formulation;
- suppliers or strains have changed;
- the marketed dose differs from the clinical dose;
- the claim is broader than the outcome measured in the study; or
- the company is relying heavily on ingredient- or species-level research rather than evidence closely matched to the finished product.
What This Means for Your Product Claims
For dietary supplement structure/function claims, FDA expects manufacturers to have substantiation showing that their claims are truthful and not misleading. The agency's guidance specifically directs companies to consider how closely the evidence relates to the product and claim being marketed.
FTC applies the same basic principle to health-related advertising: evidence should be relevant to the product and to the message consumers are likely to take from the advertising.
For probiotic strain claims, having studies on the same species is not necessarily the same as having evidence that supports the product being sold. For a probiotic product, that means collecting studies that mention the same species is not necessarily the same thing as substantiating the claim.
What matters is whether those studies provide a scientifically defensible basis for the strain, formulation and claim you are actually selling.
Different probiotic strains within the same species can produce different effects. Evidence from one strain should therefore not be transferred to another simply because the species name matches. The scientific question is whether there is a defensible evidence bridge between what was studied and what is being sold.
This article provides scientific and regulatory information for educational purposes and does not constitute legal advice. Regulatory requirements and the evidence needed to support a particular claim depend on the product, claim, context and applicable law.
- Dietrich CG, Kottmann T, Alavi M. Commercially available probiotic drinks containing Lactobacillus casei DN-114001 reduce antibiotic-associated diarrhea. World Journal of Gastroenterology. 2014;20(42):15837-15844. View study
- López P, Gueimonde M, Margolles A, Suárez A. Distinct Bifidobacterium strains drive different immune responses in vitro. International Journal of Food Microbiology. 2010;138(1-2):157-165. View study
- McFarland LV, Evans CT, Goldstein EJC. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Frontiers in Medicine. 2018;5:124. View study
- Strain-Specificity of Probiotics in Pediatrics: A Rapid Review of the Clinical Evidence. 2023. View review
- U.S. Food and Drug Administration. Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act. View FDA guidance
- Federal Trade Commission. Health Products Compliance Guidance. 2022. View FTC guidance
Protect Your Probiotic Claims Before They Become a Problem
FSC reviews the strain, dose, formulation, human evidence and proposed claims to identify what is supported, where the evidence has gaps, and what should be corrected before the claim creates regulatory, retailer or commercial risk.
Protect My Claims